Open AccessSize reduction of gastric fundic gland polyposis by de‐escalation of acid‐suppressive therapy
Author(s) -
Kanamori Akira,
Tominaga Keiichi,
Masuyama Hironori,
Ishikawa Mutsumi,
Masuyama Satoshi,
Kondo Masayuki,
Kanazawa Mimari,
Tanaka Takanao,
Yamaura Masamichi,
Abe Keiichiro,
Watanabe Shoko,
Yamamiya Akira,
Abe Yoko,
Goda Kenichi,
Irisawa Atsushi
Publication year - 2023
Publication title -
den open
Language(s) - English
Resource type - Journals
ISSN - 2692-4609
DOI - 10.1002/deo2.135
Subject(s) - esophagogastroduodenoscopy , omeprazole , reflux , refractory (planetary science) , gastroenterology , gastric acid , medicine , histamine , antagonist , proton pump inhibitor , ranitidine , stomach , disease , receptor , endoscopy , biology , astrobiology
The patient, a 73‐year‐old woman, had been taking acid‐suppressive therapy for refractory reflux esophagitis for 10 years. A potassium‐competitive acid blocker was administered to strengthen acid‐suppressive therapy for worsening symptoms of gastroesophageal reflux disease. Esophagogastroduodenoscopy showed an increase in the number and size of fundic gland polyposis (FGPs). When acid‐suppressive therapy was changed from potassium‐competitive acid blocker to proton pump inhibitor, the FGPs showed reduced size 1 year later. Furthermore, when acid‐suppressive therapy was changed from proton pump inhibitor to histamine‐2 receptor antagonist, FGPs were even smaller after 1 and 2 years. The patient, who had no flare‐up of gastroesophageal reflux disease symptoms, continues to be treated medically with histamine‐2 receptor antagonist. This case report describes changes in endoscopic findings of a patient with FGPs caused by acid‐suppressive therapy for refractory gastroesophageal reflux disease.